Shares of Kura Oncology Inc (NASDAQ:KURA) have been assigned a consensus recommendation of “Buy” from the eight ratings firms that are presently covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month price objective among analysts that have updated their coverage on the stock in the last year is $28.00.
A number of brokerages have weighed in on KURA. BidaskClub upgraded Kura Oncology from a “hold” rating to a “buy” rating in a research note on Thursday, July 12th. Oppenheimer boosted their price objective on Kura Oncology from $27.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, July 9th. HC Wainwright began coverage on Kura Oncology in a research note on Wednesday, August 1st. They issued a “buy” rating and a $31.00 price objective for the company. Finally, ValuEngine upgraded Kura Oncology from a “buy” rating to a “strong-buy” rating in a research note on Monday, July 2nd.
Hedge funds and other institutional investors have recently modified their holdings of the business. Millennium Management LLC raised its stake in shares of Kura Oncology by 0.5% during the second quarter. Millennium Management LLC now owns 524,872 shares of the company’s stock worth $9,553,000 after purchasing an additional 2,661 shares during the last quarter. Barclays PLC raised its stake in shares of Kura Oncology by 67.0% during the first quarter. Barclays PLC now owns 8,977 shares of the company’s stock worth $168,000 after purchasing an additional 3,600 shares during the last quarter. Rhumbline Advisers raised its stake in shares of Kura Oncology by 29.9% during the first quarter. Rhumbline Advisers now owns 18,095 shares of the company’s stock worth $339,000 after purchasing an additional 4,160 shares during the last quarter. Schwab Charles Investment Management Inc. raised its stake in shares of Kura Oncology by 10.3% during the first quarter. Schwab Charles Investment Management Inc. now owns 45,174 shares of the company’s stock worth $848,000 after purchasing an additional 4,200 shares during the last quarter. Finally, Alps Advisors Inc. raised its stake in shares of Kura Oncology by 19.4% during the second quarter. Alps Advisors Inc. now owns 48,400 shares of the company’s stock worth $881,000 after purchasing an additional 7,874 shares during the last quarter. Institutional investors own 77.28% of the company’s stock.
Shares of KURA opened at $15.75 on Friday. The company has a debt-to-equity ratio of 0.04, a current ratio of 10.22 and a quick ratio of 10.22. The company has a market capitalization of $664.57 million, a P/E ratio of -10.36 and a beta of 4.20. Kura Oncology has a 52-week low of $12.10 and a 52-week high of $24.02.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Thursday, August 9th. The company reported ($0.45) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.45). On average, sell-side analysts predict that Kura Oncology will post -1.73 EPS for the current fiscal year.
About Kura Oncology
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.
Featured Article: What is a Stop Order?
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.